House Bill 2824 would require health insurance carriers issuing or renewing group accident and health policies in West Virginia to cover infertility-related care. The bill defines infertility as a disease affecting an individual’s ability to become pregnant or cause a pregnancy, and it requires coverage for diagnosis of infertility, medically necessary fertility treatment, and fertility preservation services when a person faces a medical treatment likely to impair fertility, such as chemotherapy, radiation, or certain surgeries. It also includes coverage for evaluations, lab work, medications, and treatments associated with donor eggs, sperm, and embryos, and it sets the effective date for January 1, 2026.
The bill limits what insurers may do in administering this coverage. It prohibits infertility-specific deductibles, copays, coinsurance, benefit caps, waiting periods, and preexisting-condition exclusions that are different from those applied to other covered services. It also bars coverage limits based solely on arbitrary factors such as number of attempts, dollar amounts, or age, and requires any limitations to be grounded in clinical guidelines and the enrollee’s medical history. At the same time, the bill excludes experimental infertility procedures, nonmedical costs related to third-party reproduction, and reversal of voluntary sterilization, and it does not require coverage for medical costs tied to preparing a surrogate or gestational carrier in certain circumstances.
The bill would add a new article to the West Virginia Code governing access to fertility care and would direct the Insurance Commissioner to promulgate rules to implement the new requirements. Until those rules are adopted, insurers would have to follow standards of the American Society for Reproductive Medicine. The measure also includes a severability clause, meaning the rest of the article would remain in effect if part of it were struck down.
The overall sentiment reflected in the bill text is strongly supportive of expanding fertility coverage. The findings section frames infertility as a medical disease, emphasizes that treatment is often effective, and argues that insurance coverage can improve health outcomes, reduce overall costs, and help attract and retain young families in the state. No committee transcript or vote record was provided, so there is no additional recorded legislative debate or formal vote sentiment to summarize.
The main points of contention suggested by the bill’s structure are the scope and limits of required coverage. Potential areas of dispute include whether insurers should be required to cover IVF and other assisted reproductive technologies, whether age or attempt limits should be prohibited, how much discretion insurers should retain through clinical guidelines, and whether exclusions for surrogacy-related costs, experimental procedures, and sterilization reversal are appropriate. These issues primarily affect health insurers, employers offering group coverage, and patients seeking infertility diagnosis, treatment, or fertility preservation.
HB2824 would create a new insurance mandate in West Virginia by requiring group health insurance policies to cover infertility diagnosis, medically necessary fertility treatment, and fertility preservation services for patients at risk of fertility loss from medical treatment. It would constrain insurer cost-sharing and utilization limits for those benefits, require rulemaking by the Insurance Commissioner, and establish standards for coverage administration beginning January 1, 2026. The bill would primarily affect health carriers, insured employees and dependents, and patients seeking reproductive and fertility-related care.
The bill’s stated purpose and findings reflect a favorable view of expanding access to fertility care, presenting infertility as a treatable medical condition and insurance coverage as beneficial for families, health outcomes, and long-term costs. Because no committee discussion or vote history was provided, there is no recorded legislative opposition or support beyond the bill text itself. On its face, the measure is framed as a health coverage expansion with a pro-family and pro-access rationale.
Likely areas of contention include the mandate’s cost to insurers and employers, the inclusion of assisted reproductive technologies such as IVF, and the bill’s restrictions on insurer-imposed limits like age caps, attempt limits, and infertility-specific cost-sharing. Additional debate may arise over exclusions for experimental procedures, surrogacy-related costs, and reversal of voluntary sterilization, as well as how much authority insurers should retain to apply clinical guidelines. These issues would mainly be contested by insurers and employer groups on one side and fertility patients, advocates, and medical providers on the other.